Research programme: autologous T-cell therapy - Iovance Biotherapeutics

Drug Profile

Research programme: autologous T-cell therapy - Iovance Biotherapeutics

Alternative Names: HPV TIL

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer; Breast cancer; Human papillomavirus infections; Lung cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 24 Aug 2017 Iovance Biotherapeutics and H.Lee Moffitt Cancer Center plans to initiate a phase I trial of combination of tumour-infiltrating lymphocytes and nivolumab (Opdivo®) in Non-small cell lung cancer in December 2017 (Iovance Biotherapeutics pipeline, August 2017)
  • 27 Jun 2017 Lion Biotechnologies is now called Iovance Biotherapeutics
  • 26 Apr 2017 Lion Biotechnologies enters into a manufacturing services agreement with PharmaCell to manufacture Lion's autologous cell therapy products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top